Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib …
Purpose: Treatment of patients with oncogene-addicted cancers with tyrosine kinase
inhibitors (TKI) is biologically and clinically different than with cytotoxic chemotherapy. We …
inhibitors (TKI) is biologically and clinically different than with cytotoxic chemotherapy. We …
Chemotherapy with erlotinib or chemotherapy alone in advanced non‐small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors
SB Goldberg, GR Oxnard, S Digumarthy… - The …, 2013 - academic.oup.com
Purpose. Epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer has
an oncogene‐addicted biology that confers sensitivity to EGFR tyrosine kinase inhibitors …
an oncogene‐addicted biology that confers sensitivity to EGFR tyrosine kinase inhibitors …
Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A Becker, L Crombag, DAM Heideman… - European journal of …, 2011 - Elsevier
BACKGROUND: Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor
(EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an …
(EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an …
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer
Ten percent of North American patients with non–small-cell lung cancer have tumors with
somatic mutations in the gene for the epidermal growth factor receptor (EGFR) …
somatic mutations in the gene for the epidermal growth factor receptor (EGFR) …
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib
Y Xu, H Liu, J Chen, Q Zhou - Cancer biology & therapy, 2010 - Taylor & Francis
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
Purpose: Patients with epidermal growth factor receptor (EGFR)-mutant lung
adenocarcinoma develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI) after …
adenocarcinoma develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI) after …
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
Background Lung adenocarcinomas from patients who respond to the tyrosine kinase
inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function …
inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function …
[HTML][HTML] Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer
Introduction Erlotinib (Tarceva) is an epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor, which effectively targets EGFR-mutant driven non–small-cell lung cancer …
kinase inhibitor, which effectively targets EGFR-mutant driven non–small-cell lung cancer …
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
K Suda, I Murakami, T Katayama, K Tomizawa… - Clinical cancer …, 2010 - AACR
Purpose: In epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
for lung cancer patients, acquired resistance develops almost inevitably and this limits the …
for lung cancer patients, acquired resistance develops almost inevitably and this limits the …
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours
PA Jänne - Lung Cancer, 2008 - Elsevier
For patients with advanced non-small cell lung cancer (NSCLC), the introduction of the epi-
dermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib …
dermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib …
相关搜索
- lung cancer acquired resistance
- disease flare acquired resistance
- disease flare lung cancer
- kinase inhibitors acquired resistance
- lung cancer kinase inhibitors
- kinase inhibitors egfr tyrosine
- trial design acquired resistance
- lung cancer trial design
- disease flare trial design
- egfr tyrosine acquired resistance
- chemotherapy with erlotinib acquired resistance
- t790m mutation acquired resistance
- pharmacokinetic processes acquired resistance
- dosing schedules acquired resistance
- lung cancer t790m mutation
- lung cancer pharmacokinetic processes